KRAS mutation fails to predict NSCLC chemotherapy success
Research casts doubt on the ability of the KRAS mutation to aid the selection of patients with non-small-cell lung cancer to receive adjuvant chemotherapy.
Source: MedWire News - Respiratory - Category: Respiratory Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Respiratory Medicine